“A gene therapy clinical trial for hemophilia shows promise and could be approved by the FDA later this year — a feat made possible, in part, by UNC-Chapel Hill’s 70-year-old research program.”
“A gene therapy clinical trial for hemophilia shows promise and could be approved by the FDA later this year — a feat made possible, in part, by UNC-Chapel Hill’s 70-year-old research program.”